ReviewClinical interventions in aging2013
The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.
Review in Clinical interventions in aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vitamin D receptor gene ApaI polymorphism and breast cancer susceptibility: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.Journal of diabetes and its complications · 2015Trial
- Vitamin D Receptor Regulates Oxidative Stress and Apoptosis Via the HIF-1α/HO-1 Pathway in Cardiomyocytes.Cell biochemistry and biophysics · 2025Article
- Review
- Should I Supplement Vitamin D in a Patient With Sepsis?Journal of acute medicine · 2024Article
- Pre- and Postnatal Vitamin D Status and Allergy Outcomes in Early Childhood.Biomedicines · 2022Review
- Article
- Epidemiologic Data of Vitamin D Deficiency and Its Implication in Cardio-Cerebrovascular Risk in a Southern Italian Population.Journal of nutrition and metabolism · 2021Article
- Assessment of Vitamin D Levels in Patients Presenting With Chronic Low Back Pain at a Tertiary Care Hospital.Cureus · 2020Article
- Neuroprotective effect of paricalcitol in a rat model of transient global cerebral ischemia.International journal of emergency medicine · 2020Article
- Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation.International journal of molecular sciences · 2017Article
- Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients.Pediatric nephrology (Berlin, Germany) · 2017Article
- Vitamin D and acute myocardial infarction.World journal of cardiology · 2017Review
- Vitamin D and prolonged treatment with photosensitivity-associated antibiotics.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitous distribution of vitamin D receptors in the human body is responsible for the pleiotropic effects of vitamin D-receptor activation. We discuss the possible beneficial effects of a selective activator of vitamin D receptor, paricalcitol, on the cardiovascular system in chronic heart failure patients and chronic kidney patients, in light of new trials. Paricalcitol should provide additional clinical benefits over the standard treatment for chronic kidney and heart failure, especially in cases of cardiorenal syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.